Treatment of Hip Trochanteric Bursitis Using Hyaluronate Injections

Lauren Gorelick, Ayala Rozano-Gorelick, Dror Robinson, Ohad Marcus, Samia Joubran, Edward Ram

Department of Hand Surgery, Rambam Medical Center, Haifa, Israel.
Department of Psychology, Tel-Hai Academic College, Tel-Hai, Israel.
Division of General Surgery, Rabin Medical Center—Campus Golda, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Head Orthopedic Research Unit and Foot and Ankle Service Hasharon Hospital, Rabin Medical Center Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Petah Tikwa, Israel.
The Bruce Rappaport Faculty of Medicine, Techion—Israel Institute of Technology and Emek Medical Center, Haifa, Israel.

DOI: 10.4236/ojra.2013.32019                

Abstract

Trochanteric bursitis is a common cause of musculoskeletal pain and often requires medical intervention and should be distinguished from sciatica and irradiating pain of pelvic and spinal origin. Previously, the etiology of the trochanteric pain syndrome was thought to be caused by inflammation. The current study was performed in order to assess the efficacy of trochanteric injections. Methods: 158 patients were treated for trochanteric bursitis (132 females/26 males, range 22 - 88 years). 59b were treated with corticosteroid injection, 60 with hyaluronate and 39 were injected using a combination of both. Patients were followed by the HOOS score for a minimum of 12 months. Results: Pre-operative HOOS scores were similar in all groups. Following injection, the HOOS score increased from 27 ± 4 to 66 ± 2 after six months and 77 ± 4 after a year. At 12-month follow-up, the average score of patients treated by corticosteroids injection was 44 ± 7 compared with 62 ± 8 for the hyaluronate injected group and 64 ± 6 for the combination injection group. Discussion: It appears that injection therapy is highly efficacious for treating trochanteric bursitis. The effect of hyaluronate or hyaluronate and steroid combination appears to be longer lasting than that of steroid alone.

Keywords

Hip; Trochanteric Bursitis; Hyaluronic Acid; Bursitis

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	F. Silva, T. Adams, J. Feinstein and R. A. Arroyo, “Trochanteric Bursitis: Refuting the Myth of Inflammation,” Journal of Clinical Rheumatology, Vol. 14, No. 2, 2008, pp. 82-86. doi:10.1097/RHU.0b013e31816b4471
[2]	N. K. Viradia, A. A. Berger and L. E. Dahners, “Relationship between Width of Greater Trochanters and Width of Iliac Wings in Tronchanteric Bursitis,” American Journal of Orthopedics, Vol. 40, No. 9, 2011, pp. E159- E162.
[3]	P. Walker, S. Kannangara, W. J. Bruce, D. Michael and H. Van der Wall, “Lateral Hip Pain: Does Imaging Predict Response to Localized Injection?” Clinical Orthopedics and Related Research, Vol. 457, 2007, pp. 144-149.
[4]	M. B. Stephens, A. I. Beutler and F. G. O’Connor, “Musculoskeletal Injections: A Review of the Evidence,” American Family Physician, Vol. 78, No. 8, 2008, pp. 971-976.
[5]	M. Nago, Y. Mitsui, M. Gotoh, K. Nakama, I. Shirachi, F. Higuchi and K. Nagata, “Hyaluronan Modulates Cell Proliferation and mRNA Expression of Adhesion-Related Procollagens and Cytokines in Glenohumeral Synovial/ Capsular Fibroblasts in Adhesive Capsulitis,” Journal of Orthopaetic Research, Vol. 28, No. 6, 2010, pp. 726-731.
[6]	A. Brinks, R. M. van Rijn, A. M. Bohnen, G. L. Slee, J. A. Verhaar, B. W. Koes and S. M. Bierma-Zeinstra, “Effect of Corticosteroid Injection for Trochanter Pain Syndrome: Design of a Randomised Clinical Trial in General Practice,” BMC Musculoskeletal Disorders, Vol. 8, 2007, pp. 95-99. doi:10.1186/1471-2474-8-95
[7]	S. Kaasalainen and J. Crook, “An Exploration of Seniors’ Ability to Report Pain,” Clinical Nursing Research, Vol. 13, No. 3, 2004, pp. 199-215. doi:10.1177/1054773804265692
[8]	D. T. Felson, J. J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Goldsmith, L. M. Katz, R. Lightfoot Jr., H. Paulus and V. Strand, “American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 38, No. 6, 1995, pp. 727-735. doi:10.1002/art.1780380602
[9]	D. Caborn, J. Rush, W. Lanzer, D. Parenti and C. Murray, “A Randomized, Single-Blind Comparison of the Efficacy and Tolerability of Hylan G-F 20 and Triamcinolone Hexacetonide in Patients with Osteoarthritis of the Knee,” Journal of Rheumatology, Vol. 31, No. 2, 2004, pp. 333- 343.
[10]	A. Skwara, R. Ponelis, C. O. Tibesku, D. Rosenbaum and S. Fuchs-Winkelmann, “Gait Patterns after Intraarticular Treatment of Patients with Osteoarthritis of the Knee— Hyaluronan versus Triamcinolone: A Prospective, Randomized, Doubleblind, Monocentric Study,” European Journal of Medical Research, Vol. 14, No. 4, 2009, pp. 157-164.
[11]	A. Skwara, C. D. Peterlein, C. O. Tibesku, D. Rosenbaum and S. Fuchs-Winkelmann, “Changes of Gait Patterns and Muscle Activity after Intraarticular Treatment of Patients with Osteoarthritis of the Knee: A Prospective, Randomised, Doubleblind Study,” The Knee, Vol. 16, No. 6, 2009, pp. 466-472. doi:10.1016/j.knee.2009.03.003
[12]	G. S. Habib and W. Miari, “The Effect of Intra-Articular Triamcinolone Preparations on Blood Glucose Levels in Diabetic Patients: A Controlled Study,” Journal of Clinical Rheumatology, Vol. 17, No. 6, 2011, pp. 302-305. doi:10.1097/RHU.0b013e31822acd7c
[13]	S. Calve, J. Isaac, J. P. Gumucio and C. L. Mendias, “Hyaluronic Acid, HAS1 and HAS2 Are Significantly Upregulated during Muscle Hypertrophy,” American Journal of Physiology: Cell Physiology, Vol. 303, No. 5, 2012, pp. C577-C588. doi:10.1152/ajpcell.00057.2012
[14]	E. Tous, J. L. Ifkovits, K. J. Koomalsingh, T. Shuto, T. Soeda, N. Kondo, J. H. Gorman III, R. C. Gorman and J. A. Burdick, “Influence of Injectable Hyaluronic Acid Hydrogel Degradation Behavior on Infarction-Induced Ventricular Remodeling,” Biomacromolecules, Vol. 12, No. 11, 2011, pp. 4127-4135. doi:10.1021/bm201198x